ELEKTA EXTENDS ITS LINE OF STEREOTACTIC TREATMENT SOLUTIONS AT 2008 CONGRESS OF NEUROLOGICAL SURGEONS ANNUAL MEETING

ELEKTA EXTENDS ITS LINE OF STEREOTACTIC TREATMENT SOLUTIONS AT 2008 CONGRESS OF
NEUROLOGICAL SURGEONS ANNUAL MEETING

Press Release 
Orlando, Florida, September 18, 2008

Elekta, a leading provider of technology for treating cancer and neurological
conditions, today introduced Extend™*, a new stereotactic treatment program that
lets neurosurgeons and radiation oncologists apply the proven power and
precision of Gamma Knife® surgery to an even broader class of targets in the
head and neck*.


For more than twenty years, Leksell Gamma Knife surgery has been the gold
standard in intracranial radiosurgery. With its new re-locatable frame and
support for fractionated treatments, the Extend program now provides the ability
to treat large or critically located targets in the head and neck that were
previously untreatable with Gamma Knife surgery. The result is an exciting
crossover solution for neuro-oncology that combines Elekta's recognized
excellence in stereotaxy with its proven expertise in radiation medicine.

“When faced with lesions that are too large or too critically located to be
safely treated in a single session, Extend enables clinicians to divide the
radiation dose over multiple treatments,” says Mark Symons, Senior Vice
President, Stereotactic Business Unit. “It also includes the most precise
non-invasive fixation option available, allowing both neurosurgeons and
radiation oncologists to treat more patients with greater confidence.”

Other Meeting Highlights

In addition to the U.S. launch of the Extend Program, Elekta also will
demonstrate its line of neurosurgery solutions capable of handling the most
difficult cases, but flexible enough to support a comprehensive program:

• Leksell Gamma Knife® Perfexion™ a special device finely adapted to the task of
intracranial radiosurgery. 
• Elekta Axesse™ a head-to-toe radiosurgery solution for neuro-oncology that
effectively treats tumors while minimizing exposure to nearby healthy tissue.
• Leksell Stereotactic System® the world's most widely used stereotactic product
line.
• Elekta Neuromag® the world's most advanced magnetoencephalography (MEG)
system.

Symons concludes: "Professor Lars Leksell envisioned a gentler alternative to
open surgery and ultimately defined the field of stereotactic radiosurgery.
Today Elekta is still pushing the boundaries of science and technology to
redefine excellence in stereotaxy, and thereby help to redefine the future of
human care.”

*Extend™ requires 510(k) review and is not yet commercially available in the
U.S.


For further information, please contact:

Media: 
Michelle Lee, Elekta, Inc
Tel: 1- 770-670-2447, e-mail: michelle.lee@elekta.com

Inverstors:
Lena Schattauer, Investor Relations, Elekta AB
Tel: +46 8 587 257 22, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com   


About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.